GFAP and Alzheimer disease: By assessing a combination of plasma biomarkers, such as the ratio between the Aβ1–42 and Aβ1-40, p-tau217, NfL, and GFAP concentrations, it may be possible to create a novel effective panel for assessing the risk of developing AD [19, 116].